EMT is regarded as a critical regulator of metazoan embryogenesis and physiological processes such as wound healing. EMT also contributes significantly in pathologies such as tissue fibrosis and cancer metastasis. Hallmarks of EMT include: (a) the downregulation of cell adhesion molecules such as E-cadherin; (b) the increased expression of MMPs to assist in the degradation of the basement membrane; (c) the activation of the Rac/Rho/Cdc42 family small GTPase to bring about cytoskeleton rearrangement; and (d) the nuclear translocation of several transcription factors including β-catenin and the T cell factor/ lymphocyte enhancer factor 1 (TCF/LEF1) complex, Snail1, Snail2, and Twist (1, 2) . The adoption of a fibroblast-like transcription profile is crucial for the survival of the cells undergoing EMT. Several key transcription factors have been described (1); however, it is now clear that more such transcriptional regulators are required to govern the complex EMT transcriptome.
A novel protein-DNA complex directly activates fibroblast-specific protein 1 during EMT The calcium-binding fibroblast-specific protein 1 (FSP1; also known as S100A4) is a crucial facilitator of EMT. The expression of FSP1 marks an early stage of EMT, and blockade of FSP1 expression suppresses the EMT induced by TGF-β and EGF signals (3, 4) .
In this regard, a proximal cis-acting regulatory element in the FSP1 promoter, capable of interacting specifically with nuclear extracts from the fibroblasts but not the epithelium, was previously identified using EMSA. The element was termed fibroblast transcription site-1 (FTS-1), and the FTS-1 site has been shown to be crucial for the expression of FSP1 in fibroblasts (5) . Now, in this issue of the JCI, Venkov et al. report the use of FTS-1 as a probe to identify protein components of the FTS-1 complex in fibroblast nuclear extracts (6). Using 2 independent approaches, EMSA and DNA affinity chromatography, the authors identified 2 proteins, CArG box-binding factor-A (CBF-A) and KRAB-associated protein 1 (KAP-1), present in a complex with FTS-1. Furthermore, the authors report that in a kidney epithelial cell line engineered to conditionally express CBF-A, the expression of CBF-A coincided with formation of the CBF-A/KAP-1/FTS-1 complex and the de novo transcription of the FSP1 gene.
CBF-A has been described as both a transcriptional activator and a repressor in distinct genomic loci (7-9). Unlike traditional transcription factors, CBF-A recognizes a variety of DNA motifs and has an affinity for both single-stranded and doublestranded DNA (6) (7) (8) . KAP-1 is generally considered a transcriptional repressor and also interacts with the nucleosome remodeling and deacetylase (NuRD) complex (10, 11) . Such evidence suggests that the CBF-A/ KAP-1/FTS-1 complex, whose function is likely to facilitate chromatin remodeling, is a direct and major activator of FSP1 transcription during EMT. Venkov et al. (6) also show that the effects of CBF-A go beyond just the activation of the FSP1 gene. Cultured kidney epithelial cells initiate the EMT process when triggered to express CBF-A. These cells assume the spindle-shaped fibroblast morphology, exhibit increased migratory capacity, and display the transcriptional responses associated with EMT ( Figure 1 ). CBF-A thus decreases the abundance of the epithelial cell markers zona occludens 1 (ZO-1) and E-cadherin and increases the expression of fibroblast markers N-cadherin, α-SMA, vimentin, Snail1, and Twist. FTS-1 sites are also present in the promoter regions of multiple genes involved in the EMT process, and these sites are more abundant than TCF/LEF1 sites and E-boxes (Snail family protein-binding sites) (6) .
CBF-A as a regulator of the EMT transcriptome and a potential target for drug development
It has been well established that EMT plays a significant role in the pathology of tissue fibrosis and metastasis (1, 2) . Bone morphogenic protein 7 has been shown to reverse TGF-β1-induced EMT and ameliorate TGF-β1-triggered fibrosis (12) . Nevertheless, potential targets for the future development of drugs that can inhibit EMT need to be further explored.
In this regard, the CBF-A/KAP-1/FTS-1 complex qualifies as a promising therapeutic target upstream of the EMT transcriptome. This notion is supported by the broad presence of FTS-1 sites in EMTresponsive genes and also by the observation that CBF-A controls the expression of important transcription regulators of EMT such as Snail1 and Twist. Therefore, disruption of the CBF-A/KAP-1/FTS-1 complex may selectively interrupt chromatin remodeling, thus not allowing for the transcription of key EMT-inducible genes.
In summary, the work presented by Venkov et al. (6) has introduced us to the CBF-A/ KAP-1/FTS-1 complex, a regulator of the early events during EMT. Future studies of this protein-DNA complex will enrich our knowledge regarding the complex transcriptional cascades that facilitate EMT and provide further insights into the treatment of EMT-dependent diseases.
Figure 1
The CBF-A/KAP-1/FTS-1 complex is a master regulator of EMT. In an epithelial cell undergoing EMT, the CBF-A and KAP-1 proteins recognize and bind to the FTS-1 sites in the genomic DNA. The CBF-A/KAP-1/FTS-1 complex controls the expression of a wide spectrum of EMTresponsive genes, possibly via the FTS-1 sites also present in their promoters. Arrows with + or -symbols indicate whether the abundance of a given protein is increased or decreased, respectively, via the action of the CBF-A/KAP-1/FTS-1 complex. ZO-1, zona occludens 1.
